Piramal Pharma Limited — PPTs, 23-10-2024: Investor Presentation

Piramal Pharma Limited reported strong financial results for Q2 and H1 FY25, with a 17% year-over-year revenue growth to ₹2,242 crore, driven by a robust CDMO segment. EBITDA rose 28% to ₹403 crore, enhancing the margin to 18%. Notable developments include plans for an $80 million expansion at their Lexington facility and a focus on sustainability, highlighted by a new FY24 Sustainability Report. The company aims for $2 billion revenue by FY30, targeting a 25% EBITDA margin.